AnGes MG, Inc. Announces Unaudited Consolidated Earnings Results for the Nine Months Ended September 30, 2016; Provides Earnings Guidance for the Year Ending December 31, 2016
October 24, 2016 at 11:25 am
Share
AnGes MG, Inc. announced unaudited consolidated earnings results for the nine months ended September 30, 2016. For the period, the company reported net sales of JPY 256 million against JPY 320 million a year ago. Operating loss was JPY 3,760 million against JPY 3,025 million a year ago. Ordinary loss was JPY 3,812 million against JPY 2,954 million a year ago. Net loss was JPY 3,823 million or JPY 62.66 per share against JPY 3,007 million or JPY 54.41 per share a year ago.
For the year ending December 31, 2016, the company expects net sales is to be JPY 400 million, operating loss is to be JPY 6,400 million, ordinary loss is to be JPY 6,400 million and net loss is to be JPY 6,400 million or JPY 100.88 per share.
AnGes, Inc., formerly AnGes MG, Inc., is a Japan-based company mainly engaged in the development of genetic medicines. The Company is involved in the development of hepatocyte growth factor (HGF) genetic medicines, NF-KB decoy oligo and hemagglutinating virus of Japan envelope (HVJ-E) non-viral vector, among others. As of December 31, 2012, the Company had four consolidated subsidiaries. On January 31, 2013, the Company sold a 95.3% stake of a Osaka-based subsidiary to ISHIHARA SANGYO KAISHA LTD.
AnGes MG, Inc. Announces Unaudited Consolidated Earnings Results for the Nine Months Ended September 30, 2016; Provides Earnings Guidance for the Year Ending December 31, 2016
ANGES, INC. 
